Dr Ashish Bajel is a clinical Haematologist, BMT physician and the stream lead for acute leukemia and MDS at the VCCC. He has expertise in treating a range of benign and malignant haematological conditions. with special interest in acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and bone marrow transplants. He oversees the umbilical cord blood transplant and haplo-identical bone marrow transplant programs at the VCCC. Dr Bajel is the member of scientific committees in the Australasian Leukemia and Lymphoma Group (ALLG) and CIBMTR. He is committed to clinical and translational research aimed at developing new treatments for leukemias and myeloproliferative disorders. Dr Bajel has published in numerous peer reviewed journals.
Acute Leukemia and Myelodysplasia
Myeloma and Autologous Stem Cell Transplantation
Lim AB, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS. Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. Transplantation. 2015 Jan;99(1):128-32
Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, Szer J, Ritchie D, Bajel A. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Jun;20(6):781-6.
Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA; Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group.Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013 Jun;13(6):519-28.
Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1;107(7):2627-32